奥美拉唑与泮托拉唑治疗非幽门螺杆菌感染十二指肠溃疡的临床效果比较
|
摘要
目的比较奥美拉唑与泮托拉唑治疗非幽门螺杆菌感染十二指肠溃疡的临床效果。方法选取2015年1月～2017年6月于九江市柴桑区人民医院住院的84例非幽门螺杆菌感染十二指肠溃疡患者作为研究对象。依据随机数字分组法,将其分为病例组和对照组,每组各42例。病例组患者给予泮托拉唑静点,对照组患者给予奥美拉唑静点。比较两组患者的临床疗效、临床症状积分和不良反应发生情况。结果病例组患者的总有效率为97.62%,高于对照组的85.71%,差异有统计学意义(P<0.05)。两组患者治疗后的临床症状积分均明显低于治疗前,差异有统计学意义(P<0.05);病例组患者治疗后的临床症状积分明显低于对照组,差异有统计学意义(P<0.05)。病例组患者的不良反应总发生率为7.14%,与对照组的9.52%比较,差异无统计学意义(P>0.05)。结论奥美拉唑与泮托拉唑临床效果相近,不良反应无明显差异,但后者的临床症状积分明显优于前者,安全性高,值得临床推广。
Objective To compare the clinical effects of Omeprazole and Pantoprazole in the treatment of duodenal ulcer caused by non-Helicobacter pylori infection. Methods A total of 84 patients with duodenal ulcer caused by nonHelicobacter pylori infection hospitalized in People′s Hospital in Chaisang District of Jiujiang City from January 2015 to June 2017 were selected as subjects. According to the random number grouping method, the patients were divided into case group and control group, with 42 cases in each group. Pantoprazole was given to the case group and Omeprazole was given to the control group. The clinical efficacy, clinical symptom score and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the case group was 97.62%, higher than that of the control group(85.71%), the difference was statistically significant(P<0.05). The scores of clinical symptoms in the two groups after treatment were significantly lower than those before treatment, the differences were statistically significant(P<0.05). The scores of clinical symptoms in the case group after treatment were significantly lower than those in the control group, the differences were statistically significant(P<0.05). The total incidence of adverse reactions was 7.14% in the case group and 9.52% in the control group, there was no significant difference between the two groups(P>0.05). Conclusion The clinical efficacy of Omeprazole and Pantoprazole is similar, and there is no significant difference in adverse reactions, but the clinical symptom score of the latter is significantly better than the former, and the safety is high, which is worthy of clinical promotion.
Objective To compare the clinical effects of Omeprazole and Pantoprazole in the treatment of duodenal ulcer caused by non-Helicobacter pylori infection. Methods A total of 84 patients with duodenal ulcer caused by nonHelicobacter pylori infection hospitalized in People′s Hospital in Chaisang District of Jiujiang City from January 2015 to June 2017 were selected as subjects. According to the random number grouping method, the patients were divided into case group and control group, with 42 cases in each group. Pantoprazole was given to the case group and Omeprazole was given to the control group. The clinical efficacy, clinical symptom score and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the case group was 97.62%, higher than that of the control group(85.71%), the difference was statistically significant(P<0.05). The scores of clinical symptoms in the two groups after treatment were significantly lower than those before treatment, the differences were statistically significant(P<0.05). The scores of clinical symptoms in the case group after treatment were significantly lower than those in the control group, the differences were statistically significant(P<0.05). The total incidence of adverse reactions was 7.14% in the case group and 9.52% in the control group, there was no significant difference between the two groups(P>0.05). Conclusion The clinical efficacy of Omeprazole and Pantoprazole is similar, and there is no significant difference in adverse reactions, but the clinical symptom score of the latter is significantly better than the former, and the safety is high, which is worthy of clinical promotion.
引文
[1]曾豪杰.泮托拉唑与奥美拉唑治疗消化性溃疡出血治疗效果对比[J].世界华人消化杂志,2017,25(20):101-105.
[2]李薇,何书经.内镜下止血术联合泮托拉唑或奥美拉唑治疗消化性溃疡出血疗效观察[J].中国煤炭工业医学杂志,2018,21(2):130-133.
[3]吴艳姣.序贯疗法和传统疗法在消化性溃疡治疗中的临床疗效及安全性研究[J].北方药学,2016,13(4):123-124.
[4]陈碧茹,刘宇虎,陈桂权,等.雷贝拉唑钠与奥美拉唑治疗消化性溃疡的疗效及患者耐受性观察[J].广州医学院学报,2016,44(4):43-45.
[5]刘容,嵇宏亮.康复新液联合质子泵抑制剂三联疗法治疗消化性溃疡的Meta分析[J].浙江中医杂志,2016,51(5):385-386.
[6]潘隽峰,潘爱祖.雷贝拉唑联合康复新液治疗老年消化性溃疡的临床疗效分析[J].内蒙古中医药,2017,36(6):71-72.
[7]邱登波.分析消化性溃疡治疗中应用潘托拉唑与奥美拉唑的临床疗效[J].临床医药文献电子杂志,2017,4(7):1324.
[8]林存侠,罗建平.不同药物(泮托拉唑、奥美拉唑)对老年消化性溃疡治疗效果对比[J].北方药学,2017,14(31):167.
[9]邹会.泮托拉唑联合枸橼酸铋钾在胃溃疡患者中的应用效果观察[J].中国当代医药,2017,24(13):146-148.
[10]李兴国,杨雪,杨浩峰.消溃愈疡汤联合三联疗法治疗HP阳性消化性溃疡的疗效观察[J].世界中医药,2016,11(12):2611-2615.
[11]王颂歌,余会丽,马明,等.抗菌药物对幽门螺杆菌感染胃溃疡患者血清炎症因子及胃泌素指标的影响[J].中华医院感染学杂志,2016,26(11):2470-2472.
[12]兰永廷.兰索拉唑三联疗法在幽门螺旋杆菌感染十二指肠溃疡治疗中的临床应用[J].世界复合医学,2017(3):45-47.
[13]姜红梅,刘建光,杨靖.奥美拉唑与泮托拉唑辅助治疗对幽门螺杆菌阳性消化性溃疡患者免疫功能的影响[J].中国医药导报,2016,13(32):129-132.
[14]薛建波,仝建军,马丽,等.黛力新联合泮托拉唑治疗合并焦虑抑郁的上腹痛综合征的临床研究[J].中国当代医药,2017,24(1):55-58.
[15]刘仁鹏.泮托拉唑与根除幽门螺杆菌治疗对服用阿司匹林老年患者胃及十二指肠损伤的预防作用[J].中国当代医药,2016,23(34):25-27.
[16]宝音扎布.泮托拉唑和奥美拉唑治疗消化性溃疡的临床效果及安全性评价[J].内蒙古医学杂志,2017,49(6):737-738.
[17]刘鹏,胡阳黔,何旭东,等.序贯与标准的三联疗法对幽门螺杆菌阳性的消化性溃疡治疗效果的分析[J].临床消化病杂志,2017,29(5):287-290.
[18]张鹏江,李倩,贾成文,等.泮托拉唑与奥美拉唑治疗老年消化性溃疡的疗效比较[J].临床军医杂志,2013,41(12):1282-1283.
[19]李加林.泮托拉唑与奥美拉唑治疗消化性溃疡出血的临床疗效及不良反应[J].临床医药文献电子杂志,2017,4(19):3706.
[20]苏有盛,吴封.荆花胃康联合三联疗法对Hp阳性消化性溃疡患者的疗效[J].中国医药科学,2017,7(7):217.
[21]洪顺忠,王育斌,弭希峰,等.中西医结合治疗消化性溃疡合并上消化道出血的疗效分析[J].中国医药科学,2018,8(15):82-84.
[22]黄宇.注射用兰索拉唑与注射用奥美拉唑对消化性溃疡患者的疗效分析[J].中国医药科学,2017,7(8):49-51
[2]李薇,何书经.内镜下止血术联合泮托拉唑或奥美拉唑治疗消化性溃疡出血疗效观察[J].中国煤炭工业医学杂志,2018,21(2):130-133.
[3]吴艳姣.序贯疗法和传统疗法在消化性溃疡治疗中的临床疗效及安全性研究[J].北方药学,2016,13(4):123-124.
[4]陈碧茹,刘宇虎,陈桂权,等.雷贝拉唑钠与奥美拉唑治疗消化性溃疡的疗效及患者耐受性观察[J].广州医学院学报,2016,44(4):43-45.
[5]刘容,嵇宏亮.康复新液联合质子泵抑制剂三联疗法治疗消化性溃疡的Meta分析[J].浙江中医杂志,2016,51(5):385-386.
[6]潘隽峰,潘爱祖.雷贝拉唑联合康复新液治疗老年消化性溃疡的临床疗效分析[J].内蒙古中医药,2017,36(6):71-72.
[7]邱登波.分析消化性溃疡治疗中应用潘托拉唑与奥美拉唑的临床疗效[J].临床医药文献电子杂志,2017,4(7):1324.
[8]林存侠,罗建平.不同药物(泮托拉唑、奥美拉唑)对老年消化性溃疡治疗效果对比[J].北方药学,2017,14(31):167.
[9]邹会.泮托拉唑联合枸橼酸铋钾在胃溃疡患者中的应用效果观察[J].中国当代医药,2017,24(13):146-148.
[10]李兴国,杨雪,杨浩峰.消溃愈疡汤联合三联疗法治疗HP阳性消化性溃疡的疗效观察[J].世界中医药,2016,11(12):2611-2615.
[11]王颂歌,余会丽,马明,等.抗菌药物对幽门螺杆菌感染胃溃疡患者血清炎症因子及胃泌素指标的影响[J].中华医院感染学杂志,2016,26(11):2470-2472.
[12]兰永廷.兰索拉唑三联疗法在幽门螺旋杆菌感染十二指肠溃疡治疗中的临床应用[J].世界复合医学,2017(3):45-47.
[13]姜红梅,刘建光,杨靖.奥美拉唑与泮托拉唑辅助治疗对幽门螺杆菌阳性消化性溃疡患者免疫功能的影响[J].中国医药导报,2016,13(32):129-132.
[14]薛建波,仝建军,马丽,等.黛力新联合泮托拉唑治疗合并焦虑抑郁的上腹痛综合征的临床研究[J].中国当代医药,2017,24(1):55-58.
[15]刘仁鹏.泮托拉唑与根除幽门螺杆菌治疗对服用阿司匹林老年患者胃及十二指肠损伤的预防作用[J].中国当代医药,2016,23(34):25-27.
[16]宝音扎布.泮托拉唑和奥美拉唑治疗消化性溃疡的临床效果及安全性评价[J].内蒙古医学杂志,2017,49(6):737-738.
[17]刘鹏,胡阳黔,何旭东,等.序贯与标准的三联疗法对幽门螺杆菌阳性的消化性溃疡治疗效果的分析[J].临床消化病杂志,2017,29(5):287-290.
[18]张鹏江,李倩,贾成文,等.泮托拉唑与奥美拉唑治疗老年消化性溃疡的疗效比较[J].临床军医杂志,2013,41(12):1282-1283.
[19]李加林.泮托拉唑与奥美拉唑治疗消化性溃疡出血的临床疗效及不良反应[J].临床医药文献电子杂志,2017,4(19):3706.
[20]苏有盛,吴封.荆花胃康联合三联疗法对Hp阳性消化性溃疡患者的疗效[J].中国医药科学,2017,7(7):217.
[21]洪顺忠,王育斌,弭希峰,等.中西医结合治疗消化性溃疡合并上消化道出血的疗效分析[J].中国医药科学,2018,8(15):82-84.
[22]黄宇.注射用兰索拉唑与注射用奥美拉唑对消化性溃疡患者的疗效分析[J].中国医药科学,2017,7(8):49-51